MiMedx Group/$MDXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
$MDXG
Sector
Primary listing
Employees
837
Headquarters
Website
MiMedx Group Metrics
BasicAdvanced
$1B
31.98
$0.21
1.74
-
Price and volume
Market cap
$1B
Beta
1.74
52-week high
$9.71
52-week low
$5.69
Average daily volume
637K
Financial strength
Current ratio
4.392
Quick ratio
3.74
Long term debt to equity
7.945
Total debt to equity
8.522
Interest coverage (TTM)
21.67%
Profitability
EBITDA (TTM)
53.744
Gross margin (TTM)
81.45%
Net profit margin (TTM)
8.84%
Operating margin (TTM)
11.88%
Effective tax rate (TTM)
27.84%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
10.37%
Return on equity (TTM)
16.61%
Valuation
Price to earnings (TTM)
31.979
Price to revenue (TTM)
2.736
Price to book
4.62
Price to tangible book (TTM)
5.4
Price to free cash flow (TTM)
17.335
Free cash flow yield (TTM)
5.77%
Free cash flow per share (TTM)
0.39
Growth
Revenue change (TTM)
6.85%
Earnings per share change (TTM)
-60.29%
3-year revenue growth (CAGR)
12.39%
10-year revenue growth (CAGR)
8.59%
3-year earnings per share growth (CAGR)
-5.64%
10-year earnings per share growth (CAGR)
4.60%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Bulls say / Bears say
MiMedx delivered record Q2 2025 net sales of $99 million, up 13% year-over-year and surpassing consensus estimates, driven by double-digit growth in both its Wound and Surgical franchises, signaling robust demand for its core products (Reuters).
The company achieved a record adjusted EBITDA of $24 million (25% of net sales) and increased its cash balance by $12 million to $119 million in Q2 2025, reflecting strong operational efficiency and healthy cash generation (GlobeNewswire).
Management raised its full-year 2025 net sales growth outlook to low double-digits following the strong Q2 performance, demonstrating confidence in sustaining balanced, double-digit growth for the remainder of the year (GlobeNewswire).
CMS’s CY2026 Physician Fee Schedule proposal would replace Medicare’s current ASP‐based skin substitute reimbursement with a flat rate of $125.38 per cm² versus current OPPS HOPD bundled payments of about $1,738 per treatment, risking more than a 90% cut in reimbursement for MiMedx’s high‐cost biologics and compressing future revenue and margins (Investing.com).
Selling, general and administrative expenses rose 16% year‐over‐year to $64 million in Q2 2025, driven by higher commissions and legal costs, suggesting ongoing expense pressures that could limit margin expansion (GlobeNewswire (Reuters)).
Q2 2025 net income of $9.62 million on $99 million in net sales implies a net margin of around 9.7%, highlighting limited bottom‐line leverage despite an 81% gross margin and underscoring significant expense drag (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $1B as of October 27, 2025.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 31.98 as of October 27, 2025.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.